text.skipToContent text.skipToNavigation
Pharma & Biotech

Rat Neonatal Retinal Cells

Catalog #: R-RET-508

Cryopreserved ampule of Rat Neonatal Retinal Cells containing ≥200,000 cells

Compare
EA

Product Overview

CloneticsTM Neonatal Rat Retinal Cells [P3-4] are ready-to-use, high quality primary cells from Sprague Dawley rats. Cells are prepared by standardized methods and are ready for immediate culture upon thaw. Cells are cryopreserved with ≥ 0.2M viable cells per ampule.

Cells are characterized by immunostaining for neuron specific class III β-tubulin (Tuj-1), specific neuronal protein gene product (PGP 9.5), ganglion cell marker, Thy1.1 and GFAP.

Recommended mediumPNGMTM BulletKitTM

Benefits

  • Ready-To-Use 
  • No tissue dissection or animal handling required 
  • Increased data reproducibility
  • Characteristic morphology and staining tests confirm tissue origin and cell type
  • Negative for mycoplasma, bacteria, yeast and fungi
  • Certificate of Analysis (CoA) is available for every batch 

 

Applications

  • General ophthalmic research 
  • Posterior segment disease
  • Inflammation
  • Degeneration
  • Neoplasms
  • Drug delivery
  • Cell therapies
  • Toxicology and cytotoxicity
  • Gene expression

 

Content & Storage

Content

≥200,000 cryopreserved cells per ampule

Instructions

Safety Data Sheets (SDS)

Certificate of Analysis (CoA)

Please enter Lot Number, including all zeros, located on the product label and please take into account that it is case sensitive.

Subscribe to our eNewsletter

Keep up to speed on the latest scientific developments, events, tips and tools from Lonza.

Interested in our Webinars?

Need a break from your daily routine? Grab a coffee and check out our free webinars. 

Need a Quote or Any Support?

Are Lonza's primary cells and media applicable to your project? Do you need a quote or any help? Contact us and a local representative will get back to you.

We use cookies to deliver the best service to you. By continuing to browse the site, you are agreeing to our use of cookies.Ok